Gallant Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $27.1M

  • Investors
  • 22

Gallant General Information

Description

Developer of a pet health technology platform intended to provide stem cell therapy for pets. The company's services develop regenerative medicine using a pet's natural biology to treat future diseases by avoiding traditional medicine that can require daily medication and surgeries that result in difficult side effects, enabling pet owners to preserve the pet's stem cells and use them in treatment when necessary.

Contact Information

Website
www.gallant.com
Formerly Known As
Pet Labs, AngelList Talent
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 10865 Road to the Cure
  • Suite 101
  • San Diego, CA 92121
  • United States
+1 (855)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Pet Technology, Life Sciences
Corporate Office
  • 10865 Road to the Cure
  • Suite 101
  • San Diego, CA 92121
  • United States
+1 (855)

Gallant Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gallant Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 20-Sep-2024 $27.1M Completed Generating Revenue
8. Later Stage VC (Series A) 08-Jan-2024 Completed Generating Revenue
7. Debt - General 30-Jun-2023 Completed Generating Revenue
6. Early Stage VC (Series A) 12-Dec-2022 Completed Generating Revenue
5. Secondary Transaction - Private Completed Generating Revenue
4. Seed Round 28-Feb-2020 Completed Generating Revenue
3. Seed Round 16-Jul-2019 Completed Startup
2. Seed Round 15-Mar-2019 $2M $2.05M Completed Startup
1. Seed Round 26-Dec-2018 $46K $46K Completed Startup
To view Gallant’s complete valuation and funding history, request access »

Gallant Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A4
Series A3
Series A2
Series A1
Seed-3
Seed-2
Seed-1
Seed 2,046,663 $0.000010 $0.49 $0.49 1x $0.49 0.64%
Pre-Seed 800,000 $0.000010 $0.06 $0.06 1x $0.06 0.25%
To view Gallant’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Gallant Patents

  • 44

    Total Documents Applications and Grants

  • Total Patents Families

  • 17

    Granted

  • 19

    Pending

  • Expiring in next 12 mo

Gallant Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022380747-A1 Primed uterine-derived regenerative cell compositions and uses thereof Pending 04-Nov-2021
CA-3235721-A1 Primed uterine-derived regenerative cell compositions and uses thereof Pending 04-Nov-2021
EP-4426816-A1 Primed uterine-derived regenerative cell compositions and uses thereof Pending 04-Nov-2021
US-20250019662-A1 Primed uterine-derived regenerative cell compositions and uses thereof Pending 04-Nov-2021
AU-2022209856-A1 Methods for optimizing reproductive tissue derived cell yield and viability for clinical applications Pending 19-Jan-2021 C12N5/0682
To view Gallant’s complete patent history, request access »

Gallant Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gallant Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
The Finger Group Family Office Minority
Digitalis Ventures Venture Capital Minority
Hill Creek Holdings Family Office Minority
2Future Holdings Venture Capital Minority
77 Ventures Venture Capital Minority
You’re viewing 5 of 22 investors. Get the full list »

Gallant Acquisitions (1)

Gallant’s most recent deal was a Merger/Acquisition with Cook Regentec (veterinary division). The deal was made on 24-Oct-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cook Regentec (veterinary division) 24-Oct-2019 Merger/Acquisition Other Healthcare Services
To view Gallant’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Gallant FAQs

  • When was Gallant founded?

    Gallant was founded in 2018.

  • Where is Gallant headquartered?

    Gallant is headquartered in San Diego, CA.

  • What is the size of Gallant?

    Gallant has 50 total employees.

  • What industry is Gallant in?

    Gallant’s primary industry is Biotechnology.

  • Is Gallant a private or public company?

    Gallant is a Private company.

  • What is Gallant’s current revenue?

    The current revenue for Gallant is .

  • How much funding has Gallant raised over time?

    Gallant has raised $93.4M.

  • Who are Gallant’s investors?

    The Finger Group, Digitalis Ventures, Hill Creek Holdings, 2Future Holdings, and 77 Ventures are 5 of 22 investors who have invested in Gallant.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »